(Q46981314)

27 December 2017

title

Association between metabolic syndrome, diabetes mellitus and prostate cancer risk (English)

1 reference

27 December 2017

1 reference

6

1 reference

27 December 2017

author name string

Y R Lawrence

1

1 reference

27 December 2017

O Morag

2

1 reference

27 December 2017

M Benderly

3

1 reference

27 December 2017

V Boyko

4

1 reference

27 December 2017

I Novikov

5

1 reference

27 December 2017

U Goldbourt

7

1 reference

27 December 2017

S Behar

8

1 reference

27 December 2017

M Barchana

9

1 reference

27 December 2017

I Wolf

10

1 reference

27 December 2017

publication date

12 February 2013

1 reference

27 December 2017

Prostate Cancer and Prostatic Diseases

published in

1 reference

27 December 2017

volume

16

1 reference

27 December 2017

issue

2

1 reference

27 December 2017

page(s)

181-186

1 reference

27 December 2017

https://scigraph.springernature.com/pub.10.1038/pcan.2012.54

exact match

0 references

cites work

Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology.

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

The metabolic syndrome and risk of incident colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

Components of the metabolic syndrome and colorectal cancer risk; a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

21 January 2018

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

Metabolic syndrome and endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

Diabetes mellitus and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

Body size and composition and prostate cancer risk: systematic review and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

Trends in colorectal cancer incidence and mortality in the Israeli Jewish ethnic populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

Diabetes mellitus and risk of prostate cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

Diabetes mellitus and risk of prostate cancer: an updated meta-analysis based on 12 case-control and 25 cohort studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

Regional variations in cancer screening rates found in women with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

Longitudinal and age trends of metabolic syndrome and its risk factors: the Family Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

Age of onset and type of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

Comparison of body mass index, waist circumference, and waist/hip ratio in predicting incident diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

The metabolic syndrome is associated with reduced risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

The effects of metabolic conditions on prostate cancer incidence over 15 years of follow-up: results from the Olmsted County Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

Racial differences in risk of prostate cancer associated with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

Metabolic syndrome and risk of cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

Features of the metabolic syndrome and prostate cancer in African-American men

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

Kaplan–Meier methods yielded misleading results in competing risk scenarios

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

A meta-analysis of diabetes mellitus and the risk of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

Obesity, metabolic syndrome, and prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

Metabolic syndrome is associated with high grade Gleason score when prostate cancer is diagnosed on biopsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.54

31 March 2020

Identifiers

DOI

10.1038/PCAN.2012.54

1 reference

27 December 2017

1 reference

27 December 2017